首页> 外文期刊>Modern Pathology >Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts
【24h】

Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts

机译:KRAS检测技术在胰腺囊性病变诊断中的应用:618例胰腺囊肿的临床体会

获取原文
       

摘要

With improvements in abdominal imaging, detection of incidental pancreatic cysts are becoming increasingly common. Analysis of pancreatic cyst fluid from fine-needle aspiration is particularly important in identifying intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs), which have significant implications in clinical intervention and follow-up. Previous controlled studies have shown that KRAS mutations in cyst fluid are highly specific for mucinous differentiation in pancreatic cysts; however, this has not been examined in the clinical setting. Over a 6-year study period, 618 pancreatic cyst fluids obtained by fine-needle aspiration at the time of endoscopic ultrasound were tested for KRAS mutations as part of routine evaluation for a cystic neoplasm. Of the 618 specimens, 603 (98%) from 546 patients were satisfactory for molecular analysis. Patients ranged in age from 17 to 90 years (mean, 63.9 years) and were predominantly female (68%). Pancreatic cysts were relatively evenly distributed throughout the pancreas and ranged in size from 0.6 to 11.0?cm (mean, 2.3?cm). Mutations in KRAS were detected in 232 of 603 (38%) aspirates. Although sufficient for molecular analysis, 320 of 603 (53%) specimens were either less than optimal (38%) or unsatisfactory (15%) for cytopathologic diagnosis. Surgical follow-up information was available for 142 (26%) patients and consisted of 53 KRAS-mutated and 89 KRAS-wild-type cysts. Overall, KRAS mutations had a specificity of 100%, but a sensitivity of 54% for mucinous differentiation. When stratified by cyst type, KRAS had a sensitivity of 67% and 14% for IPMNs and MCNs, respectively. In summary, KRAS mutations were highly specific for mucinous differentiation, but were inadequate in identifying MCNs. Future molecular studies and the combination of other fluid markers are required to improve the detection and classification of pancreatic mucinous neoplasms by endoscopic ultrasound fine-needle aspiration.
机译:随着腹部成像的改善,偶然性胰腺囊肿的检测变得越来越普遍。通过细针抽吸术分析胰腺囊肿液对于确定导管内乳头状粘液性肿瘤(IPMN)和粘液性囊性肿瘤(MCN)尤其重要,这在临床干预和随访中具有重要意义。先前的对照研究表明,囊液中的KRAS突变对胰腺囊肿的黏液分化具有高度特异性。但是,这尚未在临床环境中进行检查。在为期6年的研究过程中,对内窥镜超声检查时细针抽吸获得的618例胰腺囊肿液的KRAS突变进行了检测,作为囊性肿瘤常规评估的一部分。在618个样本中,来自546名患者的603个样本(98%)对分子分析满意。患者年龄从17岁到90岁(平均63.9岁),主要为女性(68%)。胰腺囊肿相对较均匀地分布在整个胰腺中,大小范围为0.6至11.0?cm(平均2.3?cm)。在603例(38%)抽吸物中检测到KRAS突变。尽管足以进行分子分析,但在603个标本中,有320个(53%)对细胞病理学诊断而言不够理想(38%)或不理想(15%)。 142名(26%)患者可获得手术随访信息,包括53个KRAS突变型和89个KRAS野生型囊肿。总体而言,KRAS突变的特异性为100%,但对粘液分化的敏感性为54%。按囊肿类型分层时,KRAS对IPMN和MCN的敏感性分别为67%和14%。总而言之,KRAS突变对粘液分化具有高度特异性,但不足以鉴定MCN。为了通过内镜超声细针抽吸术改善胰腺粘液性肿瘤的检测和分类,需要进一步的分子研究和其他液体标记物的组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号